logo

For the Inventor, By the Inventor

Heidelberg, Germany

Novaliq Gmbh


USPTO Granted Patents = 52

% Expired Patents = 1.9



Trademarks = 7

Forward Citations = 898

Loading Chart...
Loading Chart...

37 inventors (with patents filed for the assignee):

goldMedal Bernhard Günther (30 out of 31 patents)

silverMedal Sonja Theisinger (19 out of 20 patents)

bronzeMedal Bastian Theisinger (19 out of 22 patents)

4.  Dieter Scherer (18 out of 20 patents)

5.  Frank Löscher (16 out of 19 patents)

6.  Anthony Pettigrew (8 out of 8 patents)

7.  Sonja Krösser (7 out of 7 patents)

8.  Ralf Grillenberger (7 out of 10 patents)

9.  Hartmut Voss (7 out of 8 patents)

10.  Kirsten Eickhoff (6 out of 6 patents)

11.  Markus Beier (5 out of 26 patents)

12.  Thomas Schlüter (4 out of 5 patents)

13.  Gesche Graf (4 out of 4 patents)

14.  Clive G Wilson (4 out of 5 patents)

15.  Chiara Silvana Leo (3 out of 5 patents)


Core Competencies:
Ophthalmic Compositions
Semifluorinated Alkanes
Ocular Neovascularization
Glaucoma Treatment
Dry Eye Disease
Pharmaceutical Compositions
Increased Intraocular Pressure
Topical Administration
Stabilized Antibody Compositions
Ciclosporin
Nebivolol
Active Ingredient Delivery

52 patents:

1. 12599607 - Pharmaceutical compositions comprising timolol (2026-04-14),
2. 12569452 - Ophthalmic compositions comprising F6H8 (2026-03-10),
3. 12496326 - Ophthalmic composition for treatment of dry eye disease (2025-12-16),
4. 12419933 - Ophthalmic composition for the treatment of uveitis (2025-09-23),
5. 12397039 - Compositions and methods for the treatment of ocular neovascularization (2025-08-26),
6. 12310977 - Use of semi-fluorinated alkanes in transdermal therapeutic systems (2025-05-27),
7. 12226422 - Ophthalmic compositions comprising tafluprost for the treatment of glaucoma (2025-02-18),
8. 12128010 - Semifluorinated compounds and their compositions (2024-10-29),
9. 12059449 - Ophthalmic composition for treatment of dry eye disease (2024-08-13),
10. RE50060 - Topical administration method (2024-07-30),
11. 12005033 - Compositions comprising mixtures of semifluorinated alkanes (2024-06-11),
12. 11987623 - Stabilized antibody compositions (2024-05-21),
13. 11896559 - Opthalmic compositions comprising F6H8 (2024-02-13),
14. RE49758 - Stabilised protein compositions based on semifluorinated alkanes (2023-12-19),
15. 11723861 - Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases (2023-08-15),
NOVALIQ GmbH is a pharmaceutical company that develops and commercializes innovative ocular therapies. Their focus lies in improving the delivery, effectiveness, and tolerability of existing drugs to treat various eye disorders. They leverage their proprietary EyeSol® technology, a water-free platform, to develop novel eye drops and eye care products. NOVALIQ's mission is to enhance patients' quality of life by providing safe and effective treatments for ocular conditions.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 22 2026

Novaliq Gmbh
52 Patents

#8 in Heidelberg

#1,015 in Germany

#13,528 in the World

Heidelberg, DE
Heidelberg, Germany

Novaliq Gmbh

Forward Citations = 898

37 inventors:

goldMedal Bernhard Günther (30 out of 31 patents)

silverMedal Sonja Theisinger (19 out of 20 patents)

bronzeMedal Bastian Theisinger (19 out of 22 patents)

4.  Dieter Scherer (18 out of 20 patents)

5.  Frank Löscher (16 out of 19 patents)

Please report any incorrect information to [email protected]
Loading…